Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339423 · ClinicalTrials.gov registry record · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
- 20
- Study locations
NCT07339423: Recruiting Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT07339423 is a Phase 3 study of Obesity that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 1,150 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07339423, a Phase 3 study of Obesity, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Primary Outcome
Measured as percentage of body weight.
Conditions Studied
Interventions
- DRUG NNC0487-0111
- DRUG Placebo (matched to NNC0487-0111)
Study Locations (20)
North Carolina
- UNC Eastowne Medical Office - Chapel Hill
- PharmQuest Life Sciences LLC - Greensboro
- Accellacare - Wilmington
South Carolina
- Medical Uni of SC Charleston - Charleston
- Coastal Carolina Research Ctr - North Charleston
- Hillcrest Clinical Research - Simpsonville
Texas
- Amarillo Medical Specialists - Amarillo
- Velocity Clinical Res-Dallas - Dallas
- Care United Research, LLC - Forney
Florida
- South Broward Research LLC - Miramar
- Clinical Neuroscience Solution - Orlando
Virginia
- Washington Cntr Weight Mgmt - Arlington
- Health Res of Hampton Roads - Newport News
Georgia
- Hope Clin Res & Wellness - Conyers
Illinois
- Endeavor Health - Skokie
Indiana
- Midwest Inst For Clin Res - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2029-08-21 |
| Phase | Phase 3 |
What NCT07339423 shows while recruiting
NCT07339423 is an interventional study that assigns participants to a tested intervention. Its 1,150 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (41% higher).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which NNC0487-0111 is the first listed.
NCT07339423 names 20 study sites across 12 states, led by North Carolina, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT07339423 about?
NCT07339423 is a clinical study titled "AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight". The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) o...
What is the current status of trial NCT07339423?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2026-02-24. Estimated completion is 2029-08-21.
What conditions does trial NCT07339423 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07339423?
The interventions under investigation include: NNC0487-0111 (DRUG), Placebo (matched to NNC0487-0111) (DRUG).
Who is sponsoring clinical trial NCT07339423?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07339423 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07339423's enrollment target sits among peer trials
1,150 68th of 1053 higher than 986 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI